H.C. Wainwright raised the firm’s price target on Artiva Biotherapeutics (ARTV) to $35 from $15 and keeps a Buy rating on the shares after the company announced initial results from the Phase 2a basket trial in B-cell autoimmune diseases, with a main focus on rheumatoid arthritis. ACR50 at six months beat the benchmark with 71% response rate and all efficacy metrics are “trending highly positive,” the analyst tells investors in a research note. H.C. Wainwright believes AlloNK plus rituximab could have a best in disease efficacy profile despite treating the most severe patients.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTV:
- Artiva Highlights AlloNK RA Data and Phase 3 Alignment
- Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)
- Artiva reports data from clinical trials evaluating AlloNK
- Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts
- Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating